These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23581572)

  • 1. Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides.
    Akbar SM; Al-Mahtab M; Khan MS
    Expert Opin Biol Ther; 2013 Jul; 13(7):1063-74. PubMed ID: 23581572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection.
    Akbar SM; Al-Mahtab M; Uddin MH; Khan MS
    Hepatobiliary Pancreat Dis Int; 2013 Aug; 12(4):363-9. PubMed ID: 23924493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic interventions in chronic hepatitis B virus infection: a review.
    Wang L; Zou ZQ; Liu CX; Liu XZ
    J Immunol Methods; 2014 May; 407():1-8. PubMed ID: 24747918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-mediated immunotherapy against chronic hepatitis B virus infection.
    Gao Y; Zhang TY; Yuan Q; Xia NS
    Hum Vaccin Immunother; 2017 Aug; 13(8):1768-1773. PubMed ID: 28521640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.
    Horiike N; Fazle Akbar SM; Michitaka K; Joukou K; Yamamoto K; Kojima N; Hiasa Y; Abe M; Onji M
    J Clin Virol; 2005 Feb; 32(2):156-61. PubMed ID: 15653419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel insights into immunotherapy for hepatitis B patients.
    Akbar SM; Al-Mahtab M; Jahan M; Yoshida O; Hiasa Y
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):267-76. PubMed ID: 26626120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B.
    Akbar SM; Furukawa S; Horiike N; Abe M; Hiasa Y; Onji M
    J Viral Hepat; 2011 Jun; 18(6):408-14. PubMed ID: 20487261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments.
    Laupèze B; Vassilev V; Badur S
    Expert Rev Gastroenterol Hepatol; 2023; 17(11):1135-1147. PubMed ID: 37847193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.
    Vandepapelière P; Lau GK; Leroux-Roels G; Horsmans Y; Gane E; Tawandee T; Merican MI; Win KM; Trepo C; Cooksley G; Wettendorff M; Ferrari C;
    Vaccine; 2007 Dec; 25(51):8585-97. PubMed ID: 18031872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
    Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
    Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B vaccines: protective efficacy and therapeutic potential.
    Michel ML; Tiollais P
    Pathol Biol (Paris); 2010 Aug; 58(4):288-95. PubMed ID: 20382485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges.
    Michel ML; Deng Q; Mancini-Bourgine M
    J Hepatol; 2011 Jun; 54(6):1286-96. PubMed ID: 21238516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.
    Fung J; Lai CL; Yuen MF
    Expert Rev Anti Infect Ther; 2010 Jun; 8(6):717-26. PubMed ID: 20521898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B surface antigen monitoring and management of chronic hepatitis B.
    Sonneveld MJ; Zoutendijk R; Janssen HL
    J Viral Hepat; 2011 Jul; 18(7):449-57. PubMed ID: 21692954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopathogenesis of Hepatitis B Virus.
    Tseng TC; Huang LR
    J Infect Dis; 2017 Nov; 216(suppl_8):S765-S770. PubMed ID: 29156047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials.
    Lobaina Y; Michel ML
    Vaccine; 2017 Apr; 35(18):2308-2314. PubMed ID: 28351734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
    Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
    J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.
    Meng Z; Chen Y; Lu M
    Front Immunol; 2019; 10():3127. PubMed ID: 32117201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.